Skip to content
2000
image of Understanding the Molecular Mechanisms of Diabetes mellitus, Hypertension, Cardiovascular Disease, and Chronic Kidney Disease: Clinical Insights and Future Perspectives

Abstract

Introduction

To decrypt the tangled interconnections that contribute to the concurrent worsening of hypertension, diabetes mellitus, cardiovascular diseases, and chronic kidney disease, this review focuses on how these interlinked health issues interact. The study aims to deepen our understanding of the complex relationships between diabetes, hypertension, CKD, and CVD, while identifying knowledge gaps that warrant further exploration.

Methods

To gain insight into the shared pathophysiological mechanisms, this review investigates endothelial dysfunction, chronic inflammation, renin-angiotensin-aldosterone system activation, sympathetic nervous system hyperactivity, insulin resistance, and dyslipidemia. Data were extracted from reputable databases and search engines, including Medline, PubMed, Google Scholar, Scopus, Web of Science, Taylor and Francis, ScienceDirect/Elsevier, and Wiley Online Library.

Results

This review emphasizes the necessity of comprehensive and integrative management strategies that account for multi-system interdependencies.

Discussion

The rising prevalence of these conditions can be mitigated through preventive strategies such as lifestyle modification, physical activity, dietary interventions, stress management, and personalized clinical monitoring. Integrated lifestyle and medical interventions can significantly reduce the burden of interrelated chronic diseases.

Conclusion

This comprehensive analysis serves as a vital resource for clinicians and researchers addressing these interconnected chronic health burdens. There is an urgent need for more targeted research into these synergistic disease mechanisms and their unified management.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chyr/10.2174/0115734021389208251113105243
2026-01-06
2026-02-27

  • From This Site

    /content/journals/chyr/10.2174/0115734021389208251113105243
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Mills K.T. Stefanescu A. He J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 2020 16 4 223 237 10.1038/s41581‑019‑0244‑2 32024986
    [Google Scholar]
  2. Abdullakhodjaeva M. Akbarova M. Pathological anatomy of the dental system and organs of the central nervous system. Tashkent Medicine 1983
    [Google Scholar]
  3. Mowry F.E. Biancardi V.C. Neuroinflammation in hypertension: The renin-angiotensin system versus pro-resolution pathways. Pharmacol. Res. 2019 144 279 291 10.1016/j.phrs.2019.04.029 31039397
    [Google Scholar]
  4. Zhou B. Carrillo-Larco R.M. Danaei G. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021 398 10304 957 980 10.1016/S0140‑6736(21)01330‑1 34450083
    [Google Scholar]
  5. Benetos A. Petrovic M. Strandberg T. Hypertension management in older and frail older patients. Circ. Res. 2019 124 7 1045 1060 10.1161/CIRCRESAHA.118.313236 30920928
    [Google Scholar]
  6. Ji H. Kim A. Ebinger J.E. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020 5 3 255 10.1001/jamacardio.2019.5306 31940010
    [Google Scholar]
  7. Franklin S.S. Gustin W. Wong N.D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997 96 1 308 315 10.1161/01.CIR.96.1.308 9236450
    [Google Scholar]
  8. Hypertension. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension
  9. Sun H. Saeedi P. Karuranga S. IDF Diabetes mellitus Atlas: Global, regional and country-level diabetes mellitus prevalence estimates for 2021 and projections for 2045. Clin. Pract. 2022 183 109119 34879977
    [Google Scholar]
  10. Banik S. Ghosh A. Prevalence of chronic kidney disease in Bangladesh: A systematic review and meta-analysis. Int. Urol. Nephrol. 2021 53 4 713 718 10.1007/s11255‑020‑02597‑6 32789568
    [Google Scholar]
  11. Langham R.G. Kalantar-Zadeh K. Bonner A. Kidney health for all: Bridging the gap in kidney health education and literacy. Oxford University Press 2022 605 612
    [Google Scholar]
  12. Carey R.M. Whelton P.K. Committee* AAHGW: Prevention, detection, evaluation, and management of high blood pressure in adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann. Intern. Med. 2018 168 5 351 358 10.7326/M17‑3203 29357392
    [Google Scholar]
  13. Lu S. Bao M.Y. Miao S.M. Prevalence of hypertension, diabetes, and dyslipidemia, and their additive effects on myocardial infarction and stroke: A cross-sectional study in Nanjing, China. Ann. Transl. Med. 2019 7 18 436 10.21037/atm.2019.09.04
    [Google Scholar]
  14. Sehestedt T. Hansen T.W. Li Y. Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertens. Res. 2011 34 6 714 721 10.1038/hr.2011.6 21307869
    [Google Scholar]
  15. Chobanian A.V. Bakris G.L. Black H.R. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003 289 19 2560 2572 10.1001/jama.289.19.2560 12748199
    [Google Scholar]
  16. Carey R.M. Calhoun D.A. Bakris G.L. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension 2018 72 5 e53 e90 10.1161/HYP.0000000000000084 30354828
    [Google Scholar]
  17. Buelt A. Richards A. Jones A.L. Hypertension: New guidelines from the international society of hypertension. Am. Fam. Physician 2021 103 12 763 765 34128614
    [Google Scholar]
  18. Chiu N. Lauffenburger J.C. Franklin J.M. Choudhry N.K. Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. Hypertens. Res. 2021 44 11 1471 1482 10.1038/s41440‑021‑00739‑6 34518648
    [Google Scholar]
  19. Muntner P. Davis B.R. Cushman W.C. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014 64 5 1012 1021 10.1161/HYPERTENSIONAHA.114.03850 25259745
    [Google Scholar]
  20. Azizi M. Saxena M. Wang Y. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA 2023 329 8 651 661 10.1001/jama.2023.0713 36853250
    [Google Scholar]
  21. Bonifant G. Weir M.R. The role of blood pressure control in the prevention of cardiorenal disease in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2023 38 2 264 270 10.1093/ndt/gfac313 36449690
    [Google Scholar]
  22. Beagley J. Guariguata L. Weil C. Motala A.A. Global estimates of undiagnosed diabetes mellitus in adults. Diabetes mellitus Res. Clin. Pract. 2014 103 2 150 160
    [Google Scholar]
  23. Pasquel F.J. Lansang M.C. Dhatariya K. Umpierrez G.E. Management of diabetes mellitus and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 9 3 174 188
    [Google Scholar]
  24. Yun J.S. Ko S.H. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism 2021 123 154838 10.1016/j.metabol.2021.154838 34333002
    [Google Scholar]
  25. Iqbal A. Heller S.R. The role of structured education in the management of hypoglycaemia. Diabetologia 2018 61 4 751 760 10.1007/s00125‑017‑4334‑z 28660491
    [Google Scholar]
  26. Jwad S.M. AL-Fatlawi HY: Types of diabetes mellitus and their effect on the immune system. J Adv Pharm Pract 2022 4 21 30
    [Google Scholar]
  27. Sugandh F.N.U. Chandio M. Raveena F.N.U. Advances in the management of diabetes mellitus mellitus: A focus on personalized medicine. Cureus 2023 15 8 e43697 10.7759/cureus.43697 37724233
    [Google Scholar]
  28. Galicia-Garcia U. Benito-Vicente A. Jebari S. Pathophysiology of type 2 diabetes mellitus mellitus. Int. J. Mol. Sci. 2020 21 17 6275 10.3390/ijms21176275 32872570
    [Google Scholar]
  29. Nathan D.M. Balkau B. Bonora E. International Expert Committee Report on the role of A1c assay in the diagnosis of diabetes mellitus. Diabetes Mellitus Mare 2009 32 1327 1333
    [Google Scholar]
  30. Organization W.H. Classification of diabetes mellitus mellitus. 2019 Available from: https://iris.who.int/bitstream/handle/10665/325182/9789241515702-eng.pdf
    [Google Scholar]
  31. Organization W.H. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus mellitus: Abbreviated report of a WHO consultation. World Health Organization 2011
    [Google Scholar]
  32. Marx N. Federici M. Schütt K. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 2023 44 39 4043 4140 10.1093/eurheartj/ehad192 37622663
    [Google Scholar]
  33. Pareek M. Bhatt D.L. Nielsen M.L. Enhanced predictive capability of a 1-hour oral glucose tolerance test: A prospective population-based cohort study. Diabetes Care 2018 41 1 171 177 10.2337/dc17‑1351 29138275
    [Google Scholar]
  34. Cowie C.C. Rust K.F. Byrd-Holt D.D. Prevalence of Diabetes Mellitus and high risk for Diabetes Mellitus using A1C criteria in the US population in 1988–2006. Diabetes Mellitus Mare 2010 33 3 562 568 20067953
    [Google Scholar]
  35. Arslanian S. Bacha F. Grey M. Marcus M.D. White N.H. Zeitler P. Evaluation and management of youth-onset type 2 diabetes mellitus: A position statement by the American Diabetes Mellitus Association. Diabetes Mellitus Mare 2018 41 12 2648 30425094
    [Google Scholar]
  36. Krhač M. Lovrenčić M.V. Update on biomarkers of glycemic control. World J. Diabetes 2019 10 1 1 15 10.4239/wjd.v10.i1.1 30697366
    [Google Scholar]
  37. Holt R.I. DeVries J.H. Hess-Fischl A. The management of type 1 Diabetes Mellitus in adults. A consensus report by the American Diabetes Mellitus Association (ADA) and the European Association for the Study of Diabetes Mellitus (EASD). Diabetes Mellitus Mare 2021 44 11 2589 2625 34593612
    [Google Scholar]
  38. Di Angelantonio E. Gao P. Khan H. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 2014 311 12 1225 1233 10.1001/jama.2014.1873 24668104
    [Google Scholar]
  39. Foteinopoulou E. Clarke C.A.L. Pattenden R.J. Impact of routine clinic measurement of serum C‐peptide in people with a clinician‐diagnosis of type 1 diabetes. Diabet. Med. 2021 38 7 e14449 10.1111/dme.14449 33131101
    [Google Scholar]
  40. Yang S. Li Y. Liu C. Wu Y. Wan Z. Shen D. Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction. Front. Endocrinol. (Lausanne) 2022 13 949535 10.3389/fendo.2022.949535 36213270
    [Google Scholar]
  41. Whelton P.K. Appel L. Charleston J. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992 267 9 1213 1220 10.1001/jama.1992.03480090061028 1586398
    [Google Scholar]
  42. Panchal K. Lawson C. Chandramouli C. Lam C. Khunti K. Zaccardi F. Diabetes mellitus and risk of heart failure in people with and without cardiovascular disease: Systematic review and meta-analysis. Clin. Pract. 2023 2 111054
    [Google Scholar]
  43. Guo N. Yang L. Wan X. Qiu D. Sun W. Ma H. Relationship between elevated circulating thrombospondin-1 levels and vascular complications in diabetes mellitus. J. Diabetes Investig. 2024 15 2 197 207 10.1111/jdi.14095 37822187
    [Google Scholar]
  44. Elendu C. Amaechi D.C. Elendu T.C. Heart failure and diabetes: Understanding the bidirectional relationship. Medicine (Baltimore) 2023 102 37 e34906 10.1097/MD.0000000000034906 37713837
    [Google Scholar]
  45. Li J. Chattopadhyay K. Xu M. Prevalence and associated factors of vascular complications among inpatients with type 2 diabetes: A retrospective database study at a tertiary care department, Ningbo, China. PLoS One 2020 15 6 e0235161 10.1371/journal.pone.0235161 32574208
    [Google Scholar]
  46. Haffner S.M. Lehto S. Rönnemaa T. Pyörälä K. Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998 339 4 229 234 10.1056/NEJM199807233390404 9673301
    [Google Scholar]
  47. Nilsson P.M. Cederholm J. Zethelius B. Eliasson B. Eeg-Olofsson K. Gudbjörnsdottir S. NDR S: Trends in blood pressure control in patients with type 2 diabetes mellitus–Data from the Swedish National Diabetes mellitus Register (NDR). Blood Press. 2011 20 6 348 354 10.3109/08037051.2011.587288 21675827
    [Google Scholar]
  48. Redon J. Cifkova R. Laurent S. Mechanisms of hypertension in the cardiometabolic syndrome. J. Hypertens. 2009 27 3 441 451 10.1097/HJH.0b013e32831e13e5 19262221
    [Google Scholar]
  49. Mogensen C.E. New treatment guidelines for a patient with diabetes and hypertension. J. Hypertens. Suppl. 2003 21 1 S25 S30 12769164
    [Google Scholar]
  50. Levin A. Stevens P.E. Bilous R.W. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013 3 1 1 150
    [Google Scholar]
  51. Zoccali C. Vanholder R. Massy Z.A. The systemic nature of CKD. Nat. Rev. Nephrol. 2017 13 6 344 358 10.1038/nrneph.2017.52 28435157
    [Google Scholar]
  52. Romagnani P. Remuzzi G. Glassock R. Chronic kidney disease. Nat. Rev. Dis. Primers 2017 3 1 17088 10.1038/nrdp.2017.88 29168475
    [Google Scholar]
  53. Fox C.S. Matsushita K. Woodward M. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet 2012 380 9854 1662 1673 10.1016/S0140‑6736(12)61350‑6 23013602
    [Google Scholar]
  54. Schiffrin E.L. Lipman M.L. Mann J.F.E. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007 116 1 85 97 10.1161/CIRCULATIONAHA.106.678342 17606856
    [Google Scholar]
  55. Gansevoort R.T. Correa-Rotter R. Hemmelgarn B.R. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013 382 9889 339 352 10.1016/S0140‑6736(13)60595‑4 23727170
    [Google Scholar]
  56. Pernomian L. Pernomian L. Baraldi Araújo Restini C. Counter-regulatory effects played by the ACE – Ang II – AT1 and ACE2 – Ang-(1–7) – Mas axes on the reactive oxygen species-mediated control of vascular function: Perspectives to pharmacological approaches in controlling vascular complications. Vasa 2014 43 6 404 414 10.1024/0301‑1526/a000387 25339158
    [Google Scholar]
  57. Favre G.A. Esnault V.L.M. Van Obberghen E. Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. Am. J. Physiol. Endocrinol. Metab. 2015 308 6 E435 E449 10.1152/ajpendo.00391.2014 25564475
    [Google Scholar]
  58. Dzau V.J. Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994 89 1 493 498 10.1161/01.CIR.89.1.493 8281685
    [Google Scholar]
  59. Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000 15 61-3.(Suppl. 6) 10.1093/ndt/15.suppl_6.61 11143994
    [Google Scholar]
  60. Wenzel U. Aldosterone and progression of renal disease. Curr. Opin. Nephrol. Hypertens. 2008 17 1 44 50 10.1097/MNH.0b013e3282f29028 18090669
    [Google Scholar]
  61. Schweda F. Salt feedback on the renin-angiotensin-aldosterone system. Pflugers Arch. 2015 467 3 565 576 10.1007/s00424‑014‑1668‑y 25502115
    [Google Scholar]
  62. Narkiewicz K. Phillips B.G. Kato M. Hering D. Bieniaszewski L. Somers V.K. Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension 2005 45 4 522 525 10.1161/01.HYP.0000160318.46725.46 15767469
    [Google Scholar]
  63. Mancia G. Grassi G. Manual of hypertension of the European Society of Hypertension. Crc Press 2014 10.1201/b17072
    [Google Scholar]
  64. Eckel R.H. Grundy S.M. Zimmet P.Z. The metabolic syndrome. Lancet 2005 365 9468 1415 1428 10.1016/S0140‑6736(05)66378‑7 15836891
    [Google Scholar]
  65. Wang C.C.L. Goalstone M.L. Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004 53 11 2735 2740 10.2337/diabetes.53.11.2735 15504952
    [Google Scholar]
  66. Moller D.E. Kaufman K.D. Metabolic syndrome: A clinical and molecular perspective. Annu. Rev. Med. 2005 56 1 45 62 10.1146/annurev.med.56.082103.104751 15660501
    [Google Scholar]
  67. Matthaei S. Stumvoll M. Kellerer M. Häring H-U. Pathophysiology and pharmacological treatment of insulin resistance. Endocr. Rev. 2000 21 6 585 618 11133066
    [Google Scholar]
  68. Samuel V.T. Shulman G.I. Mechanisms for insulin resistance: Common threads and missing links. Cell 2012 148 5 852 871 10.1016/j.cell.2012.02.017 22385956
    [Google Scholar]
  69. Samuel V.T. Shulman G.I. The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. J. Clin. Invest. 2016 126 1 12 22 10.1172/JCI77812 26727229
    [Google Scholar]
  70. Tamemoto H. Kadowaki T. Tobe K. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994 372 6502 182 186 10.1038/372182a0 7969452
    [Google Scholar]
  71. Cho H. Mu J. Kim J.K. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 2001 292 5522 1728 1731 10.1126/science.292.5522.1728 11387480
    [Google Scholar]
  72. Dresner A. Laurent D. Marcucci M. Effects of free fatty acids on glucose transport and IRS-1–associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 1999 103 2 253 259 10.1172/JCI5001 9916137
    [Google Scholar]
  73. Dong B. Qi D. Yang L. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2012 303 6 H732 H742 10.1152/ajpheart.00948.2011 22842069
    [Google Scholar]
  74. Serfaty L Capeau J. Hepatitis C, insulin resistance and diabetes: clin-ical and pathogenic data. Liver Int 2009 29 (s2): 13-25.(Suppl. 2) 10.1111/j.1478‑3231.2008.01952.x 19187069
    [Google Scholar]
  75. Gao Z. Zhang X. Zuberi A. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol. Endocrinol. 2004 18 8 2024 2034 10.1210/me.2003‑0383 15143153
    [Google Scholar]
  76. Bonora E. Kiechl S. Willeit J. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998 47 10 1643 1649 10.2337/diabetes.47.10.1643 9753305
    [Google Scholar]
  77. Tenenbaum A. Adler Y. Boyko V. Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. Am. Heart J. 2007 153 4 559 565 10.1016/j.ahj.2007.01.008 17383294
    [Google Scholar]
  78. Eddy D. Schlessinger L. Kahn R. Peskin B. Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: A mathematical analysis. Diabetes Care 2009 32 2 361 366 10.2337/dc08‑0854 19017770
    [Google Scholar]
  79. Bornfeldt K.E. Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011 14 5 575 585 10.1016/j.cmet.2011.07.015 22055501
    [Google Scholar]
  80. Laakso M. Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 2014 10 5 293 302 10.1038/nrendo.2014.29 24663222
    [Google Scholar]
  81. Ramírez E. Picatoste B. González-Bris A. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: Role of GLP-1 isoforms in Glut4 receptor trafficking. Cardiovasc. Diabetol. 2018 17 1 12 10.1186/s12933‑017‑0643‑2 29301528
    [Google Scholar]
  82. Zhou M.S. Schulman I.H. Zeng Q. Link between the renin–angiotensin system and insulin resistance: Implications for cardiovascular disease. Vasc. Med. 2012 17 5 330 341 10.1177/1358863X12450094 22814999
    [Google Scholar]
  83. Zhou M-S. Schulman I.H. Raij L. Nitric oxide, angiotensin II, and hypertension. Semin NephrolSEMIN N. Elsevier 2004 366 378
    [Google Scholar]
  84. Jia G. DeMarco V.G. Sowers J.R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat. Rev. Endocrinol. 2016 12 3 144 153 10.1038/nrendo.2015.216 26678809
    [Google Scholar]
  85. Zhou M.S. Schulman I.H. Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: Role of nuclear factor kappa B activation. J. Hypertens. 2010 28 3 527 535 10.1097/HJH.0b013e3283340da8 19898250
    [Google Scholar]
  86. Matsuura K. Hagiwara N. The pleiotropic effects of ARB in vascular endothelial progenitor cells. Curr. Vasc. Pharmacol. 2011 9 2 153 157 10.2174/157016111794519345 21143169
    [Google Scholar]
  87. Andreozzi F. Laratta E. Sciacqua A. Perticone F. Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ. Res. 2004 94 9 1211 1218 10.1161/01.RES.0000126501.34994.96 15044323
    [Google Scholar]
  88. Hadi H.A. Suwaidi J.A. Endothelial dysfunction in diabetes mellitus. Vasc. Health Risk Manag. 2007 3 6 853 876 18200806
    [Google Scholar]
  89. Stalker T.J. Skvarka C.B. Scalia R. A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J. 2003 17 11 1 19 10.1096/fj.02‑1213fje 12824289
    [Google Scholar]
  90. Yan J. Tie G. Park B. Yan Y. Nowicki P.T. Messina L.M. Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial progenitor cells. J. Vasc. Surg. 2009 50 6 1412 1422 10.1016/j.jvs.2009.08.007 19837544
    [Google Scholar]
  91. Matheus ASdM Tannus LRM, Cobas RA, Palma CCS, Negrato CA, Gomes MdB. Impact of diabetes on cardiovascular disease: An update. Int. J. Hypertens. 2013 2013 653789 10.1155/2013/653789 23533715
    [Google Scholar]
  92. Olivares-Silva F. De Gregorio N. Espitia-Corredor J. Resolvin-D1 attenuation of angiotensin II-induced cardiac inflammation in mice is associated with prevention of cardiac remodeling and hypertension. Biochim. Biophys. Acta Mol. Basis Dis. 2021 1867 12 166241 10.1016/j.bbadis.2021.166241 34400298
    [Google Scholar]
  93. Zewinger S. Reiser J. Jankowski V. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat. Immunol. 2020 21 1 30 41 10.1038/s41590‑019‑0548‑1 31819254
    [Google Scholar]
  94. Guimarães A.C. Krieger E.M. Drager L.F. Spironolactone Versus Clonidine as a fourth-drug therapy for resistant hypertension: The ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension 2018 71 4 681 690 10.1161/HYPERTENSIONAHA.117.10662 29463627
    [Google Scholar]
  95. Drummond G.R. Vinh A. Guzik T.J. Sobey C.G. Immune mechanisms of hypertension. Nat. Rev. Immunol. 2019 19 8 517 532 10.1038/s41577‑019‑0160‑5 30992524
    [Google Scholar]
  96. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006 444 7121 860 867 10.1038/nature05485 17167474
    [Google Scholar]
  97. Shoelson S.E. Lee J. Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 2006 116 7 1793 1801 10.1172/JCI29069 16823477
    [Google Scholar]
  98. Vicenová B. Vopálenský V. Burýšek L. Pospíšek M. Emerging role of interleukin-1 in cardiovascular diseases. Physiol. Res. 2009 58 4 481 498 10.33549/physiolres.931673 19093736
    [Google Scholar]
  99. Wellen K.E. Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005 115 5 1111 1119 10.1172/JCI25102 15864338
    [Google Scholar]
  100. Jyotsna F. Ahmed A. Kumar K. Exploring the Complex Connection Between Diabetes and Cardiovascular Disease: Analyzing Approaches to Mitigate Cardiovascular Risk in Patients With Diabetes. Cureus 2023 15 8 e43882 10.7759/cureus.43882 37746454
    [Google Scholar]
  101. Stenvinkel P. Heimbürger O. Lindholm B. Kaysen G.A. Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transplant. 2000 15 7 953 960 10.1093/ndt/15.7.953 10862630
    [Google Scholar]
  102. Kaysen G.A. Eiserich J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J. Am. Soc. Nephrol. 2004 15 3 538 548 10.1097/01.ASN.0000111744.00916.E6 14978155
    [Google Scholar]
  103. Trevisan R. Dodesini A.R. Lepore G. Lipids and renal disease. J. Am. Soc. Nephrol. 2006 17 2 S145 S147 10.1681/ASN.2005121320 16565240
    [Google Scholar]
  104. Jofré R. Rodriguez-Benitez P. López-Gómez J.M. Pérez-Garcia R. Inflammatory syndrome in patients on hemodialysis. J. Am. Soc. Nephrol. 2006 17 3 S274 S280 10.1681/ASN.2006080926 17130274
    [Google Scholar]
  105. Zhang Z. Zhao L. Zhou X. Meng X. Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets. Front. Immunol. 2023 13 1098725 10.3389/fimmu.2022.1098725 36703963
    [Google Scholar]
  106. Kaur R. Kaur M. Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus mellitus: molecular insights and therapeutic strategies. Cardiovasc. Diabetol. 2018 17 1 1 17 29301528
    [Google Scholar]
  107. Oria M. Meghan H. Avirginia S.V. Dietary Reference Intakes for Sodium and Potassium. Washington (DC). National Academies Press US 2019
    [Google Scholar]
  108. He F.J. Li J. MacGregor G.A. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ 2013 346 f1325 10.1136/bmj.f1325 23558162
    [Google Scholar]
  109. Shaikh A. A practical approach to hypertension management in diabetes mellitus. Diabetes Ther. 2017 8 5 981 989 10.1007/s13300‑017‑0310‑3 28929319
    [Google Scholar]
  110. Klatsky A.L. Friedman G.D. Siegelaub A.B. Gérard M.J. Alcohol consumption and blood pressure. Kaiser-Permanente Multiphasic Health Examination data. N. Engl. J. Med. 1977 296 21 1194 1200 10.1056/NEJM197705262962103 854058
    [Google Scholar]
  111. Xin X. He J. Frontini M.G. Ogden L.G. Motsamai O.I. Whelton P.K. Effects of alcohol reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension 2001 38 5 1112 1117 10.1161/hy1101.093424 11711507
    [Google Scholar]
  112. Lesniak K.T. Dubbert P.M. Exercise and hypertension. Curr. Opin. Cardiol. 2001 16 6 356 359 10.1097/00001573‑200111000‑00007 11704705
    [Google Scholar]
  113. Hayashi T. Tsumura K. Suematsu C. Okada K. Fujii S. Endo G. Walking to work and the risk for hypertension in men: The Osaka Health Survey. Ann. Intern. Med. 1999 131 1 21 26 10.7326/0003‑4819‑131‑1‑199907060‑00005 10391811
    [Google Scholar]
  114. Whelton S.P. Chin A. Xin X. He J. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 2002 136 7 493 503 10.7326/0003‑4819‑136‑7‑200204020‑00006 11926784
    [Google Scholar]
  115. Ishikawa K. Ohta T. Zhang J. Hashimoto S. Tanaka H. Influence of age and gender on exercise training-induced blood pressure reduction in systemic hypertension. Am. J. Cardiol. 1999 84 2 192 196 10.1016/S0002‑9149(99)00233‑7 10426339
    [Google Scholar]
  116. Kelley G.A. Kelley K.S. Progressive resistance exercise and resting blood pressure: A meta-analysis of randomized controlled trials. Hypertension 2000 35 3 838 843 10.1161/01.HYP.35.3.838 10720604
    [Google Scholar]
  117. Pazoki R. Dehghan A. Evangelou E. Genetic predisposition to high blood pressure and lifestyle factors: associations with midlife blood pressure levels and cardiovascular events. Circulation 2018 137 7 653 661 10.1161/CIRCULATIONAHA.117.030898 29254930
    [Google Scholar]
  118. Lifton R.P. Gharavi A.G. Geller D.S. Molecular mechanisms of human hypertension. Cell 2001 104 4 545 556 10.1016/S0092‑8674(01)00241‑0 11239411
    [Google Scholar]
  119. Sędzikowska A. Szablewski L. Human glucose transporters in renal glucose homeostasis. Int. J. Mol. Sci. 2021 22 24 13522 10.3390/ijms222413522 34948317
    [Google Scholar]
  120. Burnier M. Egan B.M. Adherence in Hypertension. Circ. Res. 2019 124 7 1124 1140 10.1161/CIRCRESAHA.118.313220 30920917
    [Google Scholar]
  121. Chatterjee S. Khunti K. Davies M.J. Type 2 diabetes mellitus. Lancet Diabetes Mellitus 2017 389 10085 2239 2251
    [Google Scholar]
  122. Ng M. Fleming T. Robinson M. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014 384 9945 766 781 10.1016/S0140‑6736(14)60460‑8 24880830
    [Google Scholar]
  123. Schulze M.B. Hoffmann K. Boeing H. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 2007 30 3 510 515 10.2337/dc06‑2089 17327313
    [Google Scholar]
  124. Schulze M.B. Hu F.B. Primary prevention of diabetes: What can be done and how much can be prevented? Annu. Rev. Public Health 2005 26 1 445 467 10.1146/annurev.publhealth.26.021304.144532 15760297
    [Google Scholar]
  125. Joost H.G. Pathogenesis, risk assessment and prevention of type 2 diabetes mellitus. Obes. Facts 2008 1 3 128 137 10.1159/000137673 20054172
    [Google Scholar]
  126. McCarthy M.I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 2010 363 24 2339 2350 10.1056/NEJMra0906948 21142536
    [Google Scholar]
  127. Ng M.C. Park K.S. Oh B. Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes 2008 57 8 2226 2233 10.2337/db07‑1583 18469204
    [Google Scholar]
  128. Wu Y. Li H. Loos R.J. Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes 2008 57 10 2834 2842 10.2337/db08‑0047 18633108
    [Google Scholar]
  129. Willett W.C. Green A. Stampfer M.J. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N. Engl. J. Med. 1987 317 21 1303 1309 10.1056/NEJM198711193172102 3683458
    [Google Scholar]
  130. Kawachi I. Colditz G.A. Stampfer M.J. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann. Intern. Med. 1993 119 10 992 1000 10.7326/0003‑4819‑119‑10‑199311150‑00005 8214996
    [Google Scholar]
  131. Manson J.E. Hu F.B. Rich-Edwards J.W. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N. Engl. J. Med. 1999 341 9 650 658 10.1056/NEJM199908263410904 10460816
    [Google Scholar]
  132. Lee I.M. Manson J.E. Hennekens C.H. Paffenbarger R.S. Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA 1993 270 23 2823 2828 10.1001/jama.1993.03510230061036 8133621
    [Google Scholar]
  133. Calle E.E. Thun M.J. Petrelli J.M. Rodriguez C. Heath C.W. Body-mass index and mortality in a prospective cohort of U.S. adults. N. Engl. J. Med. 1999 341 15 1097 1105 10.1056/NEJM199910073411501 10511607
    [Google Scholar]
  134. Zhang Y. Hu G. Dietary pattern, lifestyle factors, and cardiovascular diseases. Curr. Nutr. Rep. 2012 1 2 64 72 10.1007/s13668‑012‑0009‑z
    [Google Scholar]
  135. Collaboration E.R.F. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010 375 9733 2215 2222 10.1016/S0140‑6736(10)60484‑9 20609967
    [Google Scholar]
  136. Chan J.C. Lim L-L. Wareham N.J. The Lancet Commission on diabetes mellitus: Using data to transform Diabetes Mellitus Mare and patient lives. Lancet Diabetes Mellitus 2020 396 10267 2019 2082 33189186
    [Google Scholar]
  137. Finkle P.G. Gillespie J.W. Piper B.J. Effects of PM2. 5 Air Pollutants on Cardiovascular Health in Ohio: A Secondary Data Analysis. medRxiv 2022 2022.2010
    [Google Scholar]
  138. Hajar R. Genetics in cardiovascular disease. Heart Views 2020 21 1 55 56 10.4103/HEARTVIEWS.HEARTVIEWS_140_19 32082505
    [Google Scholar]
  139. Sun X. He J. Ji X.L. Association of chronic kidney disease with coronary heart disease and stroke risks in patients with type 2 diabetes mellitus mellitus: an observational cross-sectional study in Hangzhou, China. Chin. Med. J. (Engl.) 2017 130 1 57 63 10.4103/0366‑6999.196564 28051024
    [Google Scholar]
  140. McPherson R. Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ. Res. 2016 118 4 564 578 10.1161/CIRCRESAHA.115.306566 26892958
    [Google Scholar]
  141. Mills K.T. Xu Y. Zhang W. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015 88 5 950 957 10.1038/ki.2015.230 26221752
    [Google Scholar]
  142. Noble R. Taal M.W. Epidemiology and causes of chronic kidney disease. Medicine (Abingdon) 2019 47 9 562 566 10.1016/j.mpmed.2019.06.010
    [Google Scholar]
  143. Hill N.R. Fatoba S.T. Oke J.L. Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One 2016 11 7 e0158765 10.1371/journal.pone.0158765 27383068
    [Google Scholar]
  144. Cardona-Morrell M. Rychetnik L. Morrell S.L. Espinel P.T. Bauman A. Reduction of diabetes risk in routine clinical practice: Are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health 2010 10 1 653 10.1186/1471‑2458‑10‑653 21029469
    [Google Scholar]
  145. Pyörälä K. De Backer G. Graham I. Poole-Wilson P. Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 1994 15 10 1300 1331 7821306
    [Google Scholar]
  146. Timsina Y.P. Pandey P. Mondal I.H. Dar A.H. Non-pharmacological management of hypertension: A systematic review. Food Chem Adv 2023 3 100406 10.1016/j.focha.2023.100406
    [Google Scholar]
  147. Bailey C.J. Turner R.C. Metformin. N. Engl. J. Med. 1996 334 9 574 579 10.1056/NEJM199602293340906 8569826
    [Google Scholar]
  148. Maqbool M. Javed S. Bajwa A.A. Assessment OF pain management IN postoperative cases using different scales and questionnaires. Indo Am. J. Pharm. Sci. 2019 6 1 983 987
    [Google Scholar]
  149. Foye W.O. Foye’s principles of medicinal chemistry. Lippincott Williams & Wilkins 2008 1377
    [Google Scholar]
  150. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004 64 12 1339 1358 10.2165/00003495‑200464120‑00006 15200348
    [Google Scholar]
  151. Krentz AJ Bailey CJ Melander A Thiazolidinediones for type 2 di-abetes mellitus: New agents reduce insulin resistance but need long term clinical trials 2000 321 252 3
    [Google Scholar]
  152. Dar M.A. Qadrie Z. Navigating diabetes mellitus mellitus: Advancing forward. Asian J. Med. Sci. 2024 2 23 31
    [Google Scholar]
  153. Zinman B. Wanner C. Lachin J.M. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015 373 22 2117 2128 10.1056/NEJMoa1504720 26378978
    [Google Scholar]
  154. Perkovic V. Jardine M.J. Neal B. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260
    [Google Scholar]
  155. Frías J.P. Davies M.J. Rosenstock J. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 2021 385 6 503 515 10.1056/NEJMoa2107519 34170647
    [Google Scholar]
  156. Green J.B. Bethel M.A. Armstrong P.W. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2015 373 3 232 242 10.1056/NEJMoa1501352 26052984
    [Google Scholar]
  157. Care D. Cardiovascular disease and risk management: Standards of medical care in diabetes mellitus-2020. Diabetes Mellitus Mare 2020 43 S111 S134
    [Google Scholar]
  158. Benjamin E.J. Muntner P. Alonso A. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation 2019 139 10 e56 e528 10.1161/CIR.0000000000000659 30700139
    [Google Scholar]
  159. Lok CE Huber TS Lee T KDOQI clinical practice guideline for vascular. Am J Kidney Dis 2020 75 4 S1-S164.(Suppl. 2) 10.1053/j.ajkd.2019.12.001 32778223
    [Google Scholar]
  160. Ruggenenti P. Remuzzi G. Ti Guidelines. Circulation 2019 139 25 e1082 e1143 30586774
    [Google Scholar]
  161. Battelino T. Danne T. Bergenstal R.M. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019 42 8 1593 1603 10.2337/dci19‑0028 31177185
    [Google Scholar]
  162. Lyssenko V Laakso M Genetic screening for the risk of type 2 diabetes: worthless or valuable?Diabetes Care 2013 36(Suppl 2): S120-6.(Suppl. 2) 10.2337/dcS13‑2009 23882036
    [Google Scholar]
  163. Mega J.L. Close S.L. Wiviott S.D. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009 360 4 354 362 10.1056/NEJMoa0809171 19106084
    [Google Scholar]
  164. Johnson J.A. Pharmacogenetics in clinical practice: How far have we come and where are we going? Pharmacogenomics 2008 9 11 1537 1543 23651030
    [Google Scholar]
  165. Stokes J. Panagioti M. Alam R. Effectiveness of case management for ‘at risk’ patients in primary care: A systematic review and meta-analysis. BMJ Open 2015 5 4 e007269 25877276
    [Google Scholar]
  166. Brook R.D. Rajagopalan S. Pope C.A. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation 2010 121 21 2331 2378 10.1161/CIR.0b013e3181dbece1 20458016
    [Google Scholar]
  167. Goryakin Y. Rocco L. Suhrcke M. The impact of economic, political and health system factors on the burden of cardiovascular disease in low- and middle-income countries: A review of the evidence. Health Policy Plan. 2017 32 10 1219 1232
    [Google Scholar]
/content/journals/chyr/10.2174/0115734021389208251113105243
Loading
Understanding the Molecular Mechanisms of Diabetes mellitus, Hypertension, Cardiovascular Disease, and Chronic Kidney Disease: Clinical Insights and Future Perspectives
Bentham Science Publishers ; https://doi.org/10.2174/0115734021389208251113105243
/content/journals/chyr/10.2174/0115734021389208251113105243
/content/journals/chyr/10.2174/0115734021389208251113105243
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: diabetes ; Hypertension ; dyslipidemia ; cardiovascular disease ; lifestyle ; insulin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test